Page 229 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation
P. 229
Optimal timing and response criteria of Interim-PET in DLBCL
Prospective 59 (50-67) 122 (100) 122 (100) 17 (13.9) 19 (15.6) 27 (22.1) 59 (48.4) 38 (31.1) 30 (24.6) 40 (32.8) 14 (11.5) 57 (46.7) Prospective 222 (41.2) 317 (58.8) 118 (21.9) 142 (26.3) 192 (35.6) 205 (38.0) 110 (20.4) 118 (21.9) 105 (19.5) 61 (50-69) 246 (45.6) 539 (100) 86 (16.0) 1 (0.2) 1 (0.2) Prospective 65 (59-73) 50 (82.0) 11 (18.0) 61 (100) 18 (29.5) 19 (31.1) 19 (31.1) 35 (57.4) 21 (34.4) 25 (41) 5 (8.2) 5 (8.2) Prospective 61 (48-68) 158 (84.0) 188 (100) 30 (16.0) 25 (13.3) 51 (27.1) 40 (21.3) 70 (37.2) 68 (36.2) 10 (5.3) 63 (33.5) 75 (39.9) 47 (25) 2 (1.1) (n=33) (n=127) (n=497) (n=125) (n=188) (n=61) (n=539) (n=122) 12345678 Prospective 57 (47-65) 101 (80.8) 107 (85.6) 19 (15.2) 18 (14.4) 26 (20.8) 20 (16.0) 27 (21.6) 52 (41.6) 54 (43.2) 27 (21.6) 31 (24.8) 13 (10.4) 58 (46.4) Bologna GSTT15 HOVON84 IAEA NCRI Nordic US PETAL SAKK 5 (4) Prospective
65 (56-72)
245 (49.3)
252 (50.7)
119 (23.9)
163 (32.8)
128 (25.8)
287 (57.7)
124 (24.9)
236 (47.5)
482 (97)
13 (2.6)
87 (17.5)
86 (17.3)
2 (0.4) Retrospective
57 (45-69)
122 (96.1)
127 (100)
35 (27.6)
33 (26.0)
15 (11.8)
44 (34.6)
70 (55.1)
13 (10.2)
27 (21.3)
17 (13.4)
66 (52)
2 (1.6)
3 (2.4)
Supplemental Table 1. Baseline characteristics and I-PET results of all evaluable patients from individual studies. Retrospective
54 (45-65)
20 (60.6)
6 (18.2)
5 (15.2)
15 (45.5)
33 (100)
33 (100)
4 (12.1)
11 (33.3)
14 (42.4)
4 (12.1)
2 (6.1)
1085 (64.1)
772 (45.6)
378 (22.3)
380 (22.5)
778 (46.0)
62 (51-70)
425 (25.1)
252 (14.9)
222 (13.1)
785 (46.4)
482 (28.5)
330 (19.5)
434 (25.7)
412 (24.3)
513 (30.3)
161 (9.5)
64 (3.8)
61 (3.6)
Total
(n=1692)
1 (0.06)
8 (0.5)
3 (0.2)
Ann Arbor Stage (%)
I-PET after cycle (%)
Age (med (iqr))
Low-intermediate
High-intermediate
R-CHOP14+ 2R
Study design
Female sex (%)
Therapy (%)
RR-CHOP14
R-CHOP (not
missing
R-CHOP14
R-CHOP21
specified)
IPI (%)
missing
Low
High
1
2
3
4
1
2
3
4
227
8
